BENGALURU, April 7 (Reuters) - Indian drugmaker Shilpa Medicare Ltd has the production capacity to make 100-200 million doses of a recombinant vaccine for COVID-19, a company executive told Reuters on Wednesday. The company’s shares jumped as much as 9.2% on India’s National Stock Exchange following the news. (Reporting by Sachin Ravikumar in Bengaluru; Editing by Shounak Dasgupta)